Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 40 Results

Title
Intervention Indication Therapeutic Area Year Actions
Isatuximab in addition to carfilzomib and dexamethasone for relapsed and/or refractory multiple myeloma Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Isatuximab in Addition to Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2023 View  |  Download
Ixazomib Citrate for Newly Diagnosed Multiple Myeloma – maintenance therapy following autologous stem cell transplant Ixazomib (Ninlaro; MLN 9708; MLN 2238; ixazomib citrate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Ixazomib citrate for newly diagnosed multiple myeloma inelgible for autologous stem cell transplant– maintenance therapy Ixazomib (Ninlaro; MLN 9708; MLN 2238; ixazomib citrate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
JNJ-68284528 for relapsed or refractory multiple myeloma Ciltacabtagene Autoleucel (JNJ-68284528; LCAR-B38M CAR-T cell therapy; LCAR-B38M; JNJ 4528) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Melphalan flufenamide in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma Dexamethasone (dexamethasone sodium metasulfobenzoate) , Melphalan flufenamide hydrochloride (Ygalo; Mel-flufen; J-1) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma Carfilzomib (Kyprolis; ONO-7057) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Mezigdomide Multiple myeloma (MM) Haematological Cancer and Lymphomas 2024 View  |  Download
Phelinun for reduced intensity conditioning treatment prior to allogeneic haematopoietic stem cell transplantation Melphalan hydrochloride (Cydex; CDX-353; Phelinun) Acute myeloid leukaemia (AML) , Hodgkin lymphoma , Multiple myeloma (MM) , Neuroblastoma , Non-Hodgkin lymphoma (NHL) , Ovarian cancer Female Reproductive Cancer , Haematological Cancer and Lymphomas , Neurological Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications